KYSA-5

CD19-directed CAR T-cell therapy · Kyverna Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KYSA-5, covering 2025-10-08 to 2025-10-08. Get the full timeline:

Most recent: Clinical Trial Update: KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis [Phase 1, Phase 2]

See pricing